The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Open accessAbstract
OBJECTIVE: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). METHODS: The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12. RESULTS: < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). CONCLUSION: In patients with CM, eptinezumab 100 and 300 mg was associated with a significant reduction in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 weeks of treatment. CLINICALTRIALSGOV IDENTIFIER: NCT02974153.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Self-citationStovner, L. J., Nichols, E., Steiner, T. J., Abd-Allah, F., Abdelalim, A., Al-Raddadi, R. M., Ansha, M. G., Barac, A., Bensenor, I. M., Doan, L. P., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30322-3 · Cited by 1,908
A six-item short-form survey for measuring headache impact: The HIT-6™
Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., Cady, R., Dahlöf, C. G. H., Dowson, A., & Tepper, S. (2003) · Quality of Life Research · doi:10.1023/a:1026119331193 · Cited by 1,376
Self-citationCGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Yang, M., Rendas-Baum, R., Varon, S. F., & Kosinski, M. (2011) · Cephalalgia · doi:10.1177/0333102410379890 · Cited by 544
Response expectancies in placebo analgesia and their clinical relevance
Pollo, A., Amanzio, M., Arslanian, A., Casadio, C., Maggi, G., & Benedetti, F. (2001) · Pain · doi:10.1016/s0304-3959(01)00296-2 · Cited by 442
Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks
Kam-Hansen, S., Jakubowski, M., Kelley, J. M., Kirsch, I., Hoaglin, D. C., Kaptchuk, T. J., & Burstein, R. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006175 · Cited by 399
Tassorelli, C., Diener, H.-C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2018) · Cephalalgia · doi:10.1177/0333102418758283 · Cited by 388 · cited 2×
“PROMISE-2 was designed for consistency with guidelines recently (2018) updated by the International Headache Society Clinical Trials Standing Committee.28 It should be noted that individuals with a history or evidence of significant cardiovascular disease or any clinically significant concurrent medical condition were…”
MethodSelf-citation
Cited by
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Sacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
Croop, R., Lipton, R. B., Kudrow, D., Stock, D. A., Kamen, L., Conway, C. M., Stock, E. G., Coric, V., & Goadsby, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32544-7 · Cited by 360
Self-citationKaplon, H., & Reichert, J. M. (2021) · mAbs · doi:10.1080/19420862.2020.1860476 · Cited by 292
Metadata
- Authors
- Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Cady, R.
- Venue
- Neurology
- Published
- 2020-03-31
- Volume
- 94
- Issue
- 13
- Pages
- e1365-e1377
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3013502865
- Cited by
- 388
- References
- 25
- FWCI
- 39.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. https://app.cochat.ai/papers/10.1212/wnl.0000000000009169
- The paper
- Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Cady, R. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. https://doi.org/10.1212/wnl.0000000000009169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.